Peptic ulcer esophagogastroduodenoscopy: Difference between revisions
YazanDaaboul (talk | contribs) (Created page with "{{Peptic ulcer}} __NOTOC__ {{CMG}} ==Overview== ==Peptic ulcer esophagogastroduodenoscopy== ==References== {{Reflist|2}} Category:Gastroenterology Category:Abdominal pai...") |
YazanDaaboul (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Peptic ulcer esophagogastroduodenoscopy== | ==Peptic ulcer esophagogastroduodenoscopy== | ||
===Algorithm for the Approach to Dyspepsia=== | |||
<div style="font-size: 80%;"> | |||
{{Familytree/start}} | |||
{{Familytree|boxstyle=border: 0;| | | | | | A01 | | | | | | | | | | |A01={{F1|Age ≥ 55 or ⊕ alarm features?}}}} | |||
{{Familytree|boxstyle=border: 0;| |,|-|-|-|-|^|-|-|-|-|.| | | | | | |}} | |||
{{Familytree|boxstyle=border: 0;| B01 | | | | | | | | B02 | | | | | |B01={{F1|YES}}|B02={{F1|NO}}}} | |||
{{Familytree|boxstyle=border: 0;| |!| | | | | | | | | |!| | | | | | |}} | |||
{{Familytree|boxstyle=border: 0;| C01 | | | | | | | | C02 | | | | | |C01={{F2|Endoscopy}}|C02={{F1|''H. pylori'' prevalence?}}}} | |||
{{Familytree|boxstyle=border: 0;| |!| | | | |,|-|-|-|-|^|-|-|-|-|.| |}} | |||
{{Familytree|boxstyle=border: 0;| |!| | | | D01 | | | | | | | | D02 |D01={{F1|High}}|D02={{F1|Low}}}} | |||
{{Familytree|boxstyle=border: 0;| |!| | | | |!| | | | | | | | | |!| |}} | |||
{{Familytree|boxstyle=border: 0;| |!| | | | E01 | | | | | | | | E02 |E01={{F2|Test-and-treat strategy ± acid suppression}}|E02={{F2|Acid suppression trial}}}} | |||
{{Familytree|boxstyle=border: 0;| |`|-|-|-|-|+|-|-|-|-|-|-|-|-|-|'| |}} | |||
{{Familytree|boxstyle=border: 0;| | | | | | F01 | | | | | | | | | | |F01={{F1|If eradication therapy is indicated}}}} | |||
{{Familytree|boxstyle=border: 0;| |,|-|-|-|-|^|-|-|-|-|.| | | | | | |}} | |||
{{Familytree|boxstyle=border: 0;| G01 | | | | | | | | G02 | | | | | |G01={{F1|Clarithromycin resistance ≥ 20%}}|G02={{F1|Clarithromycin resistance < 20%}}}} | |||
{{Familytree|boxstyle=border: 0;| |!| | | | | | | | | |!| | | | | | |}} | |||
{{Familytree|boxstyle=border: 0;| H01 | | | | | | | | H02 | | | | | |H01={{F2|Quadruple or sequential therapy}}|H02={{F2|PCA or PCM or Bismuth quadruple therapy}}}} | |||
{{Familytree|boxstyle=border: 0;| |!| | | | | | | | | |!| | | | | | |}} | |||
{{Familytree|boxstyle=border: 0;| I01 | | | | | | | | I02 | | | | | |I01={{F2|PLA}}|I02={{F2|Bismuth quadruple therapy or PLA}}}} | |||
{{Familytree|boxstyle=border: 0;| |`|-|-|-|-|v|-|-|-|-|'| | | | | | |}} | |||
{{Familytree|boxstyle=border: 0;| | | | | | J01 | | | | | | | | | | |J01={{F1|Adjust Rx per susceptibility test}}}} | |||
{{Familytree|boxstyle=border: 0;| | | | | | |!| | | | | | | | | | | |}} | |||
{{Familytree|boxstyle=border: 0;| | | | | | K01 | | | | | | | | | | |K01={{F2|Consider endoscopy if treatment fails}}}} | |||
{{Familytree/end}} | |||
</div> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 17:06, 14 August 2015
|
Peptic ulcer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Surgery |
|
Case Studies |
|
2017 ACG Guidelines for Peptic Ulcer Disease |
|
Guidelines for the Indications to Test for, and to Treat, H. pylori Infection |
|
Guidlines for factors that predict the successful eradication when treating H. pylori infection |
|
Guidelines to document H. pylori antimicrobial resistance in the North America |
|
Guidelines for evaluation and testing of H. pylori antibiotic resistance |
|
Guidelines for when to test for treatment success after H. pylori eradication therapy |
|
Guidelines for penicillin allergy in patients with H. pylori infection |
|
Peptic ulcer esophagogastroduodenoscopy On the Web |
|
American Roentgen Ray Society Images of Peptic ulcer esophagogastroduodenoscopy |
|
Risk calculators and risk factors for Peptic ulcer esophagogastroduodenoscopy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Peptic ulcer esophagogastroduodenoscopy
Algorithm for the Approach to Dyspepsia
| Age ≥ 55 or ⊕ alarm features? | |||||||||||||||||||||||||||||||||||||
| YES | NO | ||||||||||||||||||||||||||||||||||||
| Endoscopy | H. pylori prevalence? | ||||||||||||||||||||||||||||||||||||
| High | Low | ||||||||||||||||||||||||||||||||||||
| Test-and-treat strategy ± acid suppression | Acid suppression trial | ||||||||||||||||||||||||||||||||||||
| If eradication therapy is indicated | |||||||||||||||||||||||||||||||||||||
| Clarithromycin resistance ≥ 20% | Clarithromycin resistance < 20% | ||||||||||||||||||||||||||||||||||||
| Quadruple or sequential therapy | PCA or PCM or Bismuth quadruple therapy | ||||||||||||||||||||||||||||||||||||
| PLA | Bismuth quadruple therapy or PLA | ||||||||||||||||||||||||||||||||||||
| Adjust Rx per susceptibility test | |||||||||||||||||||||||||||||||||||||
| Consider endoscopy if treatment fails | |||||||||||||||||||||||||||||||||||||